Infraredx, Inc.

Infraredx is focused on developing and delivering products and technologies that practitioners can harness for improved clinical decision-making. A privately funded medical device company, Infraredx has the distinction of being the only company with an intravascular imaging system that is FDA-cleared for the detection of lipid core plaques, which are known to complicate stenting.

Since its founding in 1998, Infraredx has leveraged major advances in lasers and optics to develop intelligent catheter-based coronary imaging devices. Following on the successful 2009 launch of LipiScan NIR Coronary Imaging System, and the subsequent launch of the LipiScan IVUS Coronary Imaging System, Infraredx has now introduced the TVC Imaging System – a first-in-class intravascular imaging system that assesses vessel composition and structure via integrated NIRS lipid core plaque detection and enhanced IVUS imaging to provide true vessel characterization.